Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab

Journal of Bone and Mineral Research

Volumn 29, Issue 1, 2014, Pages 158-165

  Keaveny, Tony M ^a,b   McClung, Michael R ^c   Genant, Harry K ^d,e   Zanchetta, Jose R ^f   Kendler, David ^g   Brown, Jacques P ^h   Goemaere, Stefan ⁱ   Recknor, Chris ^j   Brandi, Maria L ^k   Eastell, Richard ^l   Kopperdahl, David L ^b   Engelke, Klaus ^m,n   Fuerst, Thomas ^e   Radcliffe, Hoi Shen ^o   Libanati, Cesar ^p  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ON Diagnostics   (United States)

^c OREGON OSTEOPOROSIS CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SYNARC INC   (United States)

^f Instituto de Investigaciones Metabolicas   (Argentina)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Université Laval   (Canada)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j United Osteoporosis Centers   (United States)

^k UNIVERSITY OF FLORENCE   (Italy)

^l UNIVERSITY OF SHEFFIELD   (United Kingdom)

^m Synarc Inc   (Germany)

ⁿ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^o AMGEN LTD   (United Kingdom)

^p AMGEN INC   (United States)

more..

Author keywords

Denosumab; finite element analysis; hip strength; osteoporosis; spine strength

Indexed keywords

DENOSUMAB; PLACEBO;

ADULT; AGED; ARTICLE; BONE RADIOGRAPHY; BONE STRENGTH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFICACY; FEMALE; FEMUR; FINITE ELEMENT ANALYSIS; HIP FRACTURE; HUMAN; MIDDLE AGED; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPINE; SPINE FRACTURE; TRABECULAR BONE; TREATMENT OUTCOME;

DENOSUMAB; FINITE ELEMENT ANALYSIS; HIP STRENGTH; OSTEOPOROSIS; SPINE STRENGTH;

ABSORPTIOMETRY, PHOTON; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMECHANICAL PHENOMENA; FEMALE; FINITE ELEMENT ANALYSIS; HIP; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; SPINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84890956226     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2024     Document Type: Article

References (59)

1. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ., Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000; 157: 435-48.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 165-76.
3. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T., Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000; 141: 3478-84.
4. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95: 3597-602.
5. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C., Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-65.
6. Bolognese MA, Teglbjaerg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, Hoiseth A, Lakatos P, Moffett AH, Lorenc RS, Wang A, Libanati C., Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom. 2012; 16: 147-53.
7. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR., Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011; 26: 530-7.
8. Bessho M, Ohnishi I, Matsuyama J, Matsumoto T, Imai K, Nakamura K., Prediction of strength and strain of the proximal femur by a CT-based finite element method. J Biomech. 2007; 40: 1745-53.
9. Buckley JM, Loo K, Motherway J., Comparison of quantitative computed tomography-based measures in predicting vertebral compressive strength. Bone. 2007; 40: 767-74.
10. Cody DD, Gross GJ, Hou FJ, Spencer HJ, Goldstein SA, Fyhrie DP., Femoral strength is better predicted by finite element models than QCT and DXA. J Biomech. 1999; 32: 1013-20.
11. Crawford RP, Cann CE, Keaveny TM., Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography. Bone. 2003; 33: 744-50.
12. Imai K, Ohnishi I, Bessho M, Nakamura K., Nonlinear finite element model predicts vertebral bone strength and fracture site. Spine. 2006; 31: 1789-94.
13. Keyak JH, Falkinstein Y., Comparison of in situ and in vitro CT scan-based finite element model predictions of proximal femoral fracture load. Med Eng Phys. 2003; 25: 781-7.
14. Lengsfeld M, Schmitt J, Alter P, Kaminsky J, Leppek R., Comparison of geometry-based and CT voxel-based finite element modelling and experimental validation. Med Eng Phys. 1998; 20: 515-22.
15. Martin H, Werner J, Andresen R, Schober HC, Schmitz KP., Noninvasive assessment of stiffness and failure load of human vertebrae from CT-data. Biomed Tech (Berl). 1998; 43: 82-8.
16. Wang X, Sanyal A, Cawthon PM, Palermo L, Jekir M, Christensen J, Ensrud KE, Cummings SR, Orwoll E, Black DM, Keaveny TM., Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res. 2012; 27: 808-16.
17. Keyak JH, Sigurdsson S, Karlsdottir G, Oskarsdottir D, Sigmarsdottir A, Zhao S, Kornak J, Harris TB, Sigurdsson G, Jonsson BY, Siggeirsdottir K, Eiriksdottir G, Gudnason V, Lang TF., Male-female differences in the association between incident hip fracture and proximal femoral strength: a finite element analysis study. Bone. 2011; 48: 1239-45.
18. Kopperdahl DL, Hoffmann P, Sigurdsson S, Aspelund T, Siggeirsdottir K, Eiriksdottir G, Harris T, Gudnason VG, Keaveny TM., Enhancement of hip fracture prediction using finite element analysis of CT scans. J Bone Miner Res. 2010; 25(Suppl 1): S114.
19. Orwoll ES, Marshall LM, Nielson CM, Cummings SR, Lapidus J, Cauley JA, Ensrud K, Lane N, Hoffmann PF, Kopperdahl DL, Keaveny TM., Finite element analysis of the proximal femur and hip fracture risk in older men. J Bone Miner Res. 2009; 24: 475-83.
20. Faulkner KG, Cann CE, Hasegawa BH., Effect of bone distribution on vertebral strength: assessment with patient-specific nonlinear finite element analysis. Radiology. 1991; 179: 669-74.
21. Imai K, Ohnishi I, Yamamoto S, Nakamura K., In vivo assessment of lumbar vertebral strength in elderly women using computed tomography-based nonlinear finite element model. Spine. 2008; 33: 27-32.
22. Melton LJ 3rd, Riggs BL, Keaveny TM, Achenbach SJ, Hoffmann PF, Camp JJ, Rouleau PA, Bouxsein ML, Amin S, Atkinson EJ, Robb RA, Khosla S., Structural determinants of vertebral fracture risk. J Bone Miner Res. 2007; 22: 1885-92.
23. Melton LJ 3rd, Riggs BL, Keaveny TM, Achenbach SJ, Kopperdahl D, Camp JJ, Rouleau PA, Amin S, Atkinson EJ, Robb RA, Therneau TM, Khosla S., Relation of vertebral deformities to bone density, structure, and strength. J Bone Miner Res. 2010; 25: 1922-30.
24. Amin S, Kopperdhal DL., Melton LJ 3rd, Achenbach SJ, Therneau TM, Riggs BL, Keaveny TM, Khosla S. Association of hip strength estimates by finite-element analysis with fractures in women and men. J Bone Miner Res. 2011; 26: 1593-600.
25. Keaveny TM, Kopperdahl DL, Melton LJ 3rd, Hoffmann PF, Amin S, Riggs BL, Khosla S., Age-dependence of femoral strength in white women and men. J Bone Miner Res. 2010; 25: 994-1001.
26. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM., Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008; 23: 1974-82.
27. Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K., Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone. 2012; 50: 165-70.
28. Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA., Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2009; 94: 171-80.
29. Lian KC, Lang TF, Keyak JH, Modin GW, Rehman Q, Do L, Lane NE., Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women. Osteoporos Int. 2005; 16: 642-50.
30. Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T, Zysset P., Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. Bone. 2010; 46: 41-8.
31. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Gluer CC, Zysset PK., Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res. 2009; 24: 1672-80.
32. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA., Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res. 2007; 22: 149-57.
33. Mawatari T, Miura H, Hamai S, Shuto T, Nakashima Y, Okazaki K, Kinukawa N, Sakai S, Hoffmann PF, Iwamoto Y, Keaveny TM., Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Arthritis Rheum. 2008; 58: 3340-9.
34. Keyak JH, Koyama AK, LeBlanc A, Lu Y, Lang TF., Reduction in proximal femoral strength due to long-duration spaceflight. Bone. 2009; 44: 449-53.
35. Bonnick SL., Noninvasive assessments of bone strength. Curr Opin Endocrinol Diabetes Obes. 2007; 14: 451-7.
36. Keaveny TM., Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans. Ann NY Acad Sci. 2010; 1192: 57-65.
37. McClung MR, Zanchetta JR, Høiseth A, Kendler DL, Yuen CK, Brown JP, Stonkus S, Goemaere S, Recknor C, Woodson GC, Bolognese MA, Franek E, Brandi ML, Wang A, Libanati C., Denosumab densitometric changes assessed by quantitative computed tomgraphy at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom. 2013; 16: 250-6.
38. Morgan EF, Keaveny TM., Dependence of yield strain of human trabecular bone on anatomic site. J Biomech. 2001; 34: 569-77.
39. Morgan EF, Bayraktar HH, Keaveny TM., Trabecular bone modulus-density relationships depend on anatomic site. J Biomech. 2003; 36: 897-04.
40. Bayraktar HH, Morgan EF, Niebur GL, Morris GE, Wong EK, Keaveny TM., Comparison of the elastic and yield properties of human femoral trabecular and cortical bone tissue. J Biomech. 2004; 37: 27-35.
41. Roberts BJ, Kopperdahl DL, Thrall E, Muller JA, Keaveny TM, Bouxsein ML., Prediction of femoral strength in a sideways fall configuration using QCT-based finite element analysis. Bone. 2009; 44: S72.
42. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA., Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007; 22: 1832-41.
43. Bone HG, Brown JP, Chapurlat R, Franchimont N, Brandi ML, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster JY, Resch H, Román JA, Daizadeh NS, Wang A, Geller ML, Wagman RB, Papapoulos S., The effect of six years of denosumab treatment on new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis: results from the FREEDOM extension trial. Endocr Rev. 2012; 33: S18-22.
44. McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD., Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013; 24: 227-35.
45. Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A, Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris ES, Zanchetta J, Zerbini CA, Libanati C, Cummings SR., Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012; 27: 687-93.
46. McClung MR, Zanchetta JR, Høiseth A, Kendler DL, Yuen CK, Brown JP, Stonkus S, Goemaere S, Recknor C, Woodson GC, Bolognese MA, Franek E, Brandi ML, Wang A, Libanati C., Denosumab densitometric changes assessed by QCT at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom. 2013; 16: 250-6.
47. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J., Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010; 25: 1886-94.
48. Simon JA, Recknor C, Moffet AH, Adachi JD, Franek E, Lewiecki EM, McClung MR, Mautalen CA, Ragi Eis S, Nicholson GC, Muschitz C, Nuti R, Törring O, Wang A, Libanati C., Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause. 2013; 20: 130-7.
49. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS., Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone. 2011; 49: 151-61.
50. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG., Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009; 24: 153-61.
51. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG., Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010; 25: 72-81.
52. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK., Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009; 24: 182-95.
53. Black DM, Bouxsein ML, Marshall LM, Cummings SR, Lang TF, Cauley JA, Ensrud KE, Nielson CM, Orwoll ES., Osteoporotic Fractures in Men Research G. Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res. 2008; 23: 1326-33.
54. Bousson V, Le Bras A, Roqueplan F, Kang Y, Mitton D, Kolta S, Bergot C, Skalli W, Vicaut E, Kalender W, Engelke K, Laredo JD., Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone. Osteoporos Int. 2006; 17: 855-64.
55. Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Torring O, Gallagher JC, Farrerons J, Wang A, Franchimont N, San Martin J, Grauer A, McClung M., Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011; 96: 1727-36.
56. Keaveny TM, Bouxsein ML., Theoretical implications of the biomechanical fracture threshold. J Bone Miner Res. 2008; 23: 1541-7.
57. Riggs BL, Melton LJ 3rd., Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res. 2002; 17: 11-4.
58. Parfitt AM., High bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view. J Bone Miner Res. 2002; 17: 1558-9.
59. Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ., Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 2011; 49: 162-73.